Optimizing Investments in Kazakhstan's HIV Response
As part of a Regional initiative, Kazakhstan conducted an Human Immunodeficiency Virus (HIV) allocative efficiency analysis in 2014 to 2015 to inform more strategic investment in HIV programs. Kazakhstan continues to experience a concentrated HIV...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2016
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/2016/07/26570531/optimizing-investments-kazakhstans-hiv-response http://hdl.handle.net/10986/24965 |
| Summary: | As part of a Regional initiative,
Kazakhstan conducted an Human Immunodeficiency Virus (HIV)
allocative efficiency analysis in 2014 to 2015 to inform
more strategic investment in HIV programs. Kazakhstan
continues to experience a concentrated HIV epidemic in which
the majority of new infections occurred among key
populations, particularly PWID, MSM, prison inmates, FSW,
and their clients. Under current conditions (constant
behaviors and program coverage), new HIV infections are
projected to rise by 13 percent and deaths by 32 percent.
The epidemics among PWID and MSM are projected to account
for 67 percent of new HIV infections from 2015 to 2020 so
need to be a core focus of programs. With optimized
allocations, the cost to achieve national targets (no
increase in incidence and deaths from 2015 to 2020) would be
US 52 million dollars per year. The cost to achieve more
ambitious future HIV response targets was estimated at US 80
million dollars.In conclusion, a combination of various
efficiency gains in Kazakhstan’s HIV response can halve new
HIV infections and deaths, achieving ambitious national
targets at no additional cost. As a first priority, ART will
be essential for reducing deaths and new infections, but
unit costs need to be reviewed and reduced. A second
consistent finding is the continued need to provide HIV
services for PWID at scale. A third consistent finding is
the need to scale up programs for MSM and at least double
the current low coverage levels. Additional technical
efficiency analysis is worth considering to explore the
concrete pathways to achieve the proposed cost reductions
for ART, OST, and management costs. |
|---|